Dogwood Therapeutics (DWTX) Profit After Tax (2020 - 2026)

Dogwood Therapeutics (DWTX) has reported Profit After Tax for 7 consecutive years, with -$6.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 43.66% year-over-year to -$6.1 million; the TTM figure through Mar 2026 stood at -$33.0 million (down 28.17% YoY), while the FY2025 annual figure was -$34.3 million, down 111.3% from the prior year.
• Profit After Tax fell to -$6.1 million in Q1 2026 per DWTX's latest filing, from -$6.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$1.0 million in Q2 2024 and bottomed at -$17.1 million in Q3 2025.
• Historically, Profit After Tax has averaged -$4.6 million across 5 years, with a median of -$2.6 million in 2022.
• Annual changes were most pronounced in 2023 — Profit After Tax jumped 61.7% — and 2024, when it tumbled 950.68%.
• Dogwood Therapeutics' Profit After Tax stood at -$2.0 million in 2022, then jumped by 46.04% to -$1.1 million in 2023, then sank by 950.68% to -$11.6 million in 2024, then surged by 48.17% to -$6.0 million in 2025, then dropped by 1.88% to -$6.1 million in 2026.
• Business Quant data shows DWTX's Profit After Tax at -$6.1 million in Q1 2026, -$6.0 million in Q4 2025, and -$17.1 million in Q3 2025.